Opinion|Videos|March 11, 2025
Quality of Life and Patient Outcomes in mCRC Treatment
Experts discuss practical strategies used by their institutions to manage treatment-related toxicities with third-line therapies for metastatic colorectal cancer (mCRC) and share their experiences on how third-line therapy options have impacted patients’ quality of life.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What practical strategies does your institution use to manage treatment-related toxicities with third-line therapies for mCRC?
- In your experience, how have the third-line therapy options impacted your patients’ quality of life?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
TrumpRx Launch Brings Savings—and Uncertainty
2
How Do GLP-1 Agonists Fit Into Stroke Care?
3
Addressing Disparities at Every Step of the Stroke Care Pathway: Luke Messac, MD, PhD
4
Aligning Treatment Goals in IgA Nephropathy: Applying KDIGO’s Dual-Pathway Framework to Clinical Decision-Making
5
